PsoriasisPro Health Care Providers Website

  • Home
  • Registration
  • Important Safety Information
  • Contact Us

Forgot your password?


  • Clobex® Products
    • Clobex® Spray, 0.05%
    • Clobex® Shampoo, 0.05%
    • Clobex® Lotion, 0.05%
  • Vectical® Ointment
    • Product Information
    • Data Library
  • Dermatology Tools
    • Managed Care
    • Patient Savings
    • Patient Education
  • Clinical Highlights
    • The Role of Vitamin D
    • Vitamin D3 Ointment
    • Sustained Use of Vectical®
    • Clobex® Spray vs Taclonex® Ointment
    • Clobex® Spray for Scalp Psoriasis
  • Featured Presentations
    • Ointments Differentiation
    • Vectical® Efficacy/Safety
    • Topical Vitamin D Safety
    • Clobex® Shampoo Data
    • Clobex® Lotion Data
  • Psoriasis In-Depth
    • Epidemiology
    • Risk Factors
    • Comorbidities
    • Clinical Manifestations
    • Quality of Life
    • Treatment
    • Clinical Pearls
    • Video Highlight
  • Physician Extenders

Site Map

  • HOME
  • Clobex® Products
    • Clobex® Spray Product Information
    • Data Library
    • Clobex® Shampoo Product Information
    • Data Library
    • Clobex® Lotion Product Information
    • Data Library
  • Vectical® Ointment
    • Product Information
    • Data Library
  • Dermatology Tools
    • Managed Care
    • Patient Savings
    • Patient Education
  • Clinical Highlights
    • The Role of Vitamin D
    • Vitamin D3 Ointment
    • Sustained Use of Vectical®
    • Clobex® Spray vs Taclonex® Ointment
    • Clobex® Spray for Scalp Psoriasis
  • Featured Presentations
    • A Clinical Review of the Differentiation of Calcitriol 3 µg/g Ointment and Calcipotriene 50 µg/g Ointment in Subjects With Mild to Moderate Chronic Plaque Psoriasis
    • Clinical Review of Efficacy and Long-term Safety Data of Vectical® (calcitriol) Ointment 3 µg/g
    • Use of Topical Vitamin D Therapy for Psoriasis: 52 Week Long Term Safety Data
    • Clobex® (clobetasol propionate) Shampoo, 0.05%
    • Clobex® (clobetasol propionate) Lotion, 0.05%
  • Psoriasis In-Depth
    • Epidemiology
    • Risk Factors
    • Comorbidities
    • Clinical Manifestations
    • Quality of Life
    • Treatment
    • Clinical Pearls
    • Challenges and Options in Psoriasis Treatment
  • Physician Extenders
    • Psoriasis Overview
    • Patient Support
    • About Clobex®
    • About Vectical®
  • Legal
  • Privacy
  • Registration
  • Offer Sign-Up
  • Contact Us

Important Safety Information for Clobex® Products

Clobex® (clobetasol propionate), 0.05%, is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis.

Clobetasol propionate has been shown to suppress the HPA axis at the lowest doses tested.

Adverse events associated with use of Clobex® (clobetasol propionate, 0.05%) Spray, Lotion and/or Shampoo include burning/stinging, skin dryness, irritation, erythema, hyperpigmentation, telangiectasia and skin atrophy. In clinical trials, these side effects were typically mild in nature and transient.

Clobex® Spray, Lotion and Shampoo, 0.05%, are not recommended for use on anyone younger than 18 years of age. Clobetasol propionate, 0.05%, should not be used on the face, groin or axillae, and the total dosage should not exceed 50 g (50 mL or 1.75 fl oz of Shampoo or Lotion, or 59 mL or 2 fl oz of Spray) per week. Patients should use Clobex® Shampoo, 0.05%, Clobex® Spray, 0.05%, or Clobex® Lotion, 0.05%, only for the minimum period necessary to achieve desired results, and treatment beyond 2 weeks in psoriasis should be weighed against the potential risk for HPA axis suppression. Pregnancy Category C.

Click here for full Prescribing Information for Clobex® Spray.
Click here for full Prescribing Information for Clobex® Shampoo.
Click here for full Prescribing Information for Clobex® Lotion.

Important Safety Information for Vectical® Ointment

Vectical® (calcitriol) Ointment 3 mcg/g is a topical treatment for mild to moderate plaque psoriasis in adults 18 years and older.

The most frequent adverse events (≥3%) reported in clinical trials were lab test abnormality, urine abnormality, psoriasis, hypercalciuria, pruritus and skin discomfort. Vectical® should be used with caution in patients with known or suspected disturbances in calcium homeostasis, who are taking calcium or Vitamin D supplements or who are on diuretics. If aberrations in parameters of calcium metabolism occur, discontinue use until these normalize. Caution patients to avoid excessive exposure to natural or artificial sunlight after applying the ointment. Avoid contact with eyes, lips and face. Limit use to 200 grams per week.

Click here for full Prescribing Information for Vectical® Ointment.

Galderma

Legal  |  Privacy  |  Site Map  |  Contact Us  |  Galderma Laboratories, L.P.

© 2011 Galderma Laboratories, L.P. United States. All Rights Reserved. GALDERMA, Vectical and Clobex are registered trademarks. All other trademarks are the property of their respective owners.

This site intended for US audiences only.

Galderma Laboratories, L.P.  | 14501 N. Freeway  | Fort Worth, TX 76177

Full Prescribing Information:
Clobex® (clobetasol propionate) Spray, 0.05%
Clobex® Shampoo, 0.05%
Clobex® Lotion, 0.05%
Vectical® (calcitriol) Ointment 3 mcg/g